Author: Baig, Mohammad Hassan; Sharma, Tanuj; Ahmad, Irfan; Abohashrh, Mohammed; Alam, Mohammad Mahtab; Dong, Jae-June
Title: Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study Cord-id: 5ui1x2v5 Document date: 2021_3_17
ID: 5ui1x2v5
Snippet: The COVID-19 outbreak continues to spread worldwide at a rapid rate. Currently, the absence of any effective antiviral treatment is the major concern for the global population. The reports of the occurrence of various point mutations within the important therapeutic target protein of SARS-CoV-2 has elevated the problem. The SARS-CoV-2 main protease (Mpro) is a major therapeutic target for new antiviral designs. In this study, the efficacy of PF-00835231 was investigated (a Mpro inhibitor under c
Document: The COVID-19 outbreak continues to spread worldwide at a rapid rate. Currently, the absence of any effective antiviral treatment is the major concern for the global population. The reports of the occurrence of various point mutations within the important therapeutic target protein of SARS-CoV-2 has elevated the problem. The SARS-CoV-2 main protease (Mpro) is a major therapeutic target for new antiviral designs. In this study, the efficacy of PF-00835231 was investigated (a Mpro inhibitor under clinical trials) against the Mpro and their reported mutants. Various in silico approaches were used to investigate and compare the efficacy of PF-00835231 and five drugs previously documented to inhibit the Mpro. Our study shows that PF-00835231 is not only effective against the wild type but demonstrates a high affinity against the studied mutants as well.
Search related documents:
Co phrase search for related documents- action mode and low mutation: 1
- action mode and low mutation rate: 1
- active form and low affinity: 1, 2
- active form and low mutation: 1
- active site and long range: 1, 2, 3, 4, 5
- active site and low affinity: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date